We are focussing on evolution of science to bring forward a novel peptide therapy for one of the highest contributors of pain and physical disability worldwide: Rheumatoid arthritis
ISSAR has developed a novel synthetic peptide therapeutically targeting joints, which is currently under preclinical trials. We are hoping to improve the quality of life for patients suffering with Rheumatoid arthritis in the near future.
Bones and Joints
The WHO and UN have recognized four major musculoskeletal conditions contributing to a major burden on individuals and health care systems across the world. These include; osteoarthritis, rheumatoid arthritis, osteoporosis and lower back pain.
These conditions have severe long lasting impacts of pain and physical disability affecting massive populations across the world. The prevalence and incidence of these conditions increases with age, lifestyle and other physical aspects.
Our Work In Bones and Joints
Rheumatoid arthritis:
Introduction and prevalence
In a GBD study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis (RA) was observed to be the 42nd highest contributor for global physical disability.
Manifestations
It is an autoimmune inflammatory disease which manifests as painful swelling of joints, particularly in the wrists, hands and knees accompanied by fever, fatigue, stiffness in one or more joints and weakness.
Treatment
Studies have revealed that new immunomodulatory treatment approaches have shown promising results for RA. Researchers have identified convincing results for the potential of peptide therapeutics for patients affected with RA. Since these naturally occurring peptides play a dual role of modulation and regulation of the abnormal immune responses and inflammatory mediators, they offer notable benefits over some of the current approaches used for RA.
ISSAR has developed a novel peptide drug for angiogenesis related diseases and inflammatory disorders. This novel peptide drug designated as IS-181 targets the VEGFR-2 which is the major receptor for angiogenesis function.
IS-181 causes modulation of VEGFR-2 receptors which are the major receptors for angiogenesis function by down regulating MAPK/ p38/ ERK1/2 pathways.
Our Focused Therapies
